Clearstead Advisors’s Enanta Pharmaceuticals ENTA Stock Holding History

Clearstead Advisors’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$59	Buy	+4	New	+$54	﹤0.01%	3454
2025 Q4	–	Sell	-56	Closed	-$671	–	2898
2025 Q3	$671	Buy	56 +47	+522%	+$376	﹤0.01%	2688
2025 Q2	$69	Buy	+9	New	+$54	﹤0.01%	2650
2023 Q4	–	Sell	-5,064	Closed	-$56.6K	–	1558
2023 Q3	$56.6K	Buy	+5,064	New	+$81.6K	﹤0.01%	865
2022 Q3	–	Sell	-5,064	Closed	-$239K	–	1274
2022 Q2	$239K	Hold	5,064	–	–	0.02%	352
2022 Q1	$360K	Hold	5,064	–	–	0.02%	314
2021 Q4	$379K	Hold	5,064	–	–	0.03%	291
2021 Q3	$288K	Hold	5,064	–	–	0.02%	318
2021 Q2	$223K	Hold	5,064	–	–	0.02%	329
2021 Q1	$250K	Hold	5,064	–	–	0.02%	303
2020 Q4	$213K	Hold	5,064	–	–	0.02%	313
2020 Q3	$232K	Hold	5,064	–	–	0.02%	264
2020 Q2	$254K	Hold	5,064	–	–	0.03%	240
2020 Q1	$260K	Hold	5,064	–	–	0.04%	209
2019 Q4	$313K	Hold	5,064	–	–	0.04%	218
2019 Q3	$304K	Hold	5,064	–	–	0.04%	214
2019 Q2	$427K	Hold	5,064	–	–	0.06%	184
2019 Q1	$484K	Hold	5,064	–	–	0.07%	173
2018 Q4	$359K	Hold	5,064	–	–	0.06%	190
2018 Q3	$433K	Hold	5,064	–	–	0.06%	168
2018 Q2	$587K	Hold	5,064	–	–	0.08%	133
2018 Q1	$410K	Hold	5,064	–	–	0.06%	154
2017 Q4	$297K	Hold	5,064	–	–	0.04%	179
2017 Q3	$237K	Buy	+5,064	New	+$204K	0.03%	218

Other funds holding ENTA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

CCIA

Campbell & Co Investment Adviser Baltimore, Maryland $1.91B AUM 17.57% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Clearstead Advisors's ENTA Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Enanta Pharmaceuticals (ENTA) in Q2 2026: 4 shares worth $59. The stake represents ﹤0.01% of the portfolio and ranks #3454 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in ENTA as recently as Q3 2025.

Clearstead Advisors first reported a position in ENTA in Q3 2017 and has held it in 24 quarters since. The position peaked at $587K in Q2 2018. 40 funds tracked by Wall St. Rank hold ENTA as of Q2 2026.

Clearstead Advisors held 4 shares of Enanta Pharmaceuticals worth $59 as of Q2 2026.
Enanta Pharmaceuticals was a new Clearstead Advisors position in Q2 2026.
Enanta Pharmaceuticals made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3454 holding.
Clearstead Advisors first reported a position in Enanta Pharmaceuticals in Q3 2017 and has held it in 24 quarters since.
Clearstead Advisors's Enanta Pharmaceuticals position peaked at $587K in Q2 2018.
40 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.